Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $55.01 USD
Change Today -0.20 / -0.36%
Volume 1.1M
PTCT On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $78.72
52 Week Low
05/27/14 - $19.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

ptc therapeutics inc (PTCT) Related Bloomberg News

View More Bloomberg News

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and PTC672, an antibacterial development candidate for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program. The company was founded in 1998 and is based in South Plainfield, New Jersey.

187 Employees
Last Reported Date: 03/2/15
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $495.0K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Chief Medical Officer
Total Annual Compensation: $329.3K
Compensation as of Fiscal Year 2014.

ptc therapeutics inc (PTCT) Key Developments

PTC Therapeutics, Inc. Announces German Federal Joint Committee Issues Positive Medical Benefit Rating for Translarna™ in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. announced that the Benefit Assessment by Germany's Federal Joint Committee (G-BA) indicated that Translarna (ataluren) provided a benefit for ambulatory patients aged five years and older with nonsense mutation Duchenne Muscular Dystrophy (nmDMD). The G-BA came to the decision that the existing clinical data package presented by PTC provided convincing evidence for the demonstration of a clinically meaningful added benefit. PTC received a 3 in the rating system established under the German pharmaceutical law.

PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

PTC Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $7,482,000 compared to $9,217,000 a year ago. Loss from operations was $38,071,000 compared to $14,212,000 a year ago. Net loss was $37,915,000 compared to $14,098,000 a year ago. Basic and diluted net loss per share was $1.15 compared to $0.58 a year ago.

PTC Therapeutics, Inc.'s Cancer Stem Cell Program Targeting BMI1 Enters into Phase 1

PTC Therapeutics, Inc. announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a Phase 1 study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics of PTC596, an orally available small molecule. PTC's BMI1 program is supported by a collaboration with the Wellcome Trust. BMI1 has been implicated in a wide variety of cancers and has been demonstrated to contribute to therapeutic resistance and treatment failure. BMI1 is thought to play a role in the survival and maintenance of tumor stem cells in many cancers, including central nervous system cancers such as glioblastoma. Elevated levels of BMI1 have been associated with advanced tumor grade and a poor prognosis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $55.01 USD -0.20

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 77.4x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at